Although OncoKB indicates FDA approval for erdafitinib in FGFR3-mutated bladder cancer, there are currently no FDA-approved treatments tailored specifically to patients with FGFR3 oncogenic mutant pancreatic cancer [32]. The gene discussed is FGFR3; the disease is urinary bladder cancer.